Join
Live feed
·
PRReleasevia Quantisnow
Deciphera Pharmaceuticals Inc. logo

Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet

ByQuantisnow·Wall Street's wire, on your screen.
DCPH· Deciphera Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DCPH (Deciphera Pharmaceuticals Inc.) and more on Quantisnow.